Biosimilars Market Analysis by Product (Monoclonal antibodies, Erythropoietin, Recombinant human growth hormone), by Type of Manufacturing (In-house, Contract), by Indication (Chronic disorders, Oncology, Autoimmune diseases), and by Region - Forecast to 2029

Request Sample Page

The global biosimilars market size is estimated to be USD 16.9 billion in 2021 and is expected to witness a CAGR of 39.37% during the forecast period. The economical nature of biosimilar drugs is expected to be a major factor in its rising demand. The increasing number of original biologic drug patents getting expired and growing prevalence of chronic diseases worldwide are other main factors that drive the growth. However, presence of strict regulatory rules in various countries for the development and manufacturing of the biosimilars is expected to deter the market growth.

Global Biosimilars Market Size (USD Million), 2021-2029

Source: Erevna Healthcare

By Product

Based on the product, the biosimilars market is segmented into insulin, monoclonal antibodies, interferons, glucagon, recombinant glycosylated proteins, recombinant human growth hormone, erythropoietin, calcitonin, etanercept, enoxaparin sodium, follitropin, granulocyte-colony stimulating factor, and teriparatide. In 2021, the monoclonal antibody segment accounted for the largest revenue share due to the increase in the incidence of cancer and the growing number of product launch and drug approvals. The infliximab subsegment is projected to grow at an attractive CAGR during the forecast period. This is due to the rising prevalence of autoimmune diseases globally.

By Manufacturing Type

Based on the manufacturing type, the market is categorized into in-house and contract manufacturing. In 2021, the contract manufacturing accounted for the highest revenue share because of its ease of adoption and high flexibility for the players, especially those without sufficient infrastructure or resources to be deployed.

By Indication

Based on the indication, the market is categorized into blood disorders, autoimmune disease, oncology, infectious disease, chronic disorders, and other diseases. In 2021, the oncology segment accounted for the highest revenue share owing to the increased prevalence of cancer indications such as colorectal, breast, liver, blood, and lung cancer. The second most lucrative segment is the blood disorders segment. This segment is expected to grow because of the rise in the demand for innovative therapeutic medications for diseases such as hemophilia and anemia.

Regional Insights

In 2021, Europe accounted for the highest revenue share in the global biosimilars market and is expected to maintain its position during the forecast period. This can be attributed to the favorable European laws & regulations by the regulatory bodies for biosimilar drug approval and manufacturing. In Europe, the UK, Italy, Spain, Germany, and France, are expected to witness lucrative growth in the near future. North America is expected to grow at the fastest CAGR during the forecast period owing to a rise in the incidence of cancer, blood disorders, autoimmune diseases, and others; increasing adoption of biosimilar drugs; and patent expiry of the major biologic drugs in the U.S.

Competitor Insights

Some of the key players in the biosimilars market are JCR Pharmaceuticals (Japan), Apotex (Canada), Amega Biotech (Argentina),   Merck KgaA (Germany), Amgen (US), Biogen (US), Samsung Biologics (South Korea), Fresenius Kabi AG (Germany), Mylan (US), Pfizer (US), Eli Lilly (US), Sandoz (Germany), Biocon (India), Teva Pharmaceutical (Israel), Gedeon Richter (Hungary), Boehringer Ingelheim (Germany), Dr. Reddy’s Laboratories (India), Celltrion (South Korea), mAbxience (Switzerland), Chong Kun Dang (South Korea), Coherus Bioscience (US), Gan & Lee Pharmaceuticals (China), Biocad (Russia), Stada Arzneimittel AG (Germany), and Probiomed (Mexico). The major players functioning in the biosimilars industry are adopting different strategies such as mergers & acquisitions, collaborations, and new product launches for maximizing revenue generation.

This exhaustive research report focuses on market size and forecast at global, segmental, regional and country level along with key market trends and dynamics from 2021 to 2029. The biosimilars market report is categorized into the following segments and subsegments:

Biosimilars Market, By Product (Revenue, 2021 – 2029, USD Billion)

  • Monoclonal antibodies
    • Infliximab
    • Rituximab
    • Trastuzumab
    • Adalimumab
    • Others
  • Recombinant human growth hormone (rhGH)
  • Etanercept
  • Interferon
  • Glucagon
  • Insulin
  • Follitropin
  • Calcitonin
  • Enoxaparin sodium
  • Teriparatide

Biosimilars Market, By Manufacturing (Revenue, 2021 – 2029, USD Billion)

  • Contract Manufacturing
  • In-House Manufacturing

Biosimilars Market, By Indication (Revenue, 2021 – 2029, USD Billion)

  • Oncology
  • Blood Disorders
  • Autoimmune Disease
  • Infectious Disease
  • Offsite Treatment
  • Chronic Disorder
  • Others

Biosimilars Market, By Region (Revenue, 2021 – 2029, USD Billion)

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Spain
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of APAC
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of LATAM
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • Rest of MEA

Scope of Biosimilars Market Report:

Key Parameters Details
Base Year
  • 2021
Forecast Period
  • 2022-2029
Study Coverage
  • Global and regional market size and revenue forecast
  • Segment market size and revenue forecast at global, regional, and country level
  • Competitive landscape (company share analysis, company profiles, recent development, competitive map analysis)
  • Conclusion and recommendations
Qualitative Analysis
  • Market drivers
  • Market restraints
  • Market opportunities
  • Recent market trends
  • Market challenges
  • Porter’s Five Forces analysis
  • PEST analysis
  • Value-chain analysis
  • COVID-19 impact analysis
Regional Market Scope
  • North America (U.S. and Canada)
  • Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
  • Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
  • Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
  • MEA (South Africa, GCC, Rest of MEA)
Company Profiles
  • Exhaustive profiles of top 15 players
  • 50+ other major players listing
15% Free Customization Available
  • You can customize the study scope to meet your exact requirement. Click here for more details

Table of Contents: Biosimilars Market 2021-2029

  1. Research Methodology
    1. Study Objectives
    2. Study Scope
    3. Research Assumptions
    4. Research Framework
      1. Research Models
        1. Bottom-up Approach
        2. Top-down Approach
        3. Data Triangulation
      2. Data Procurement
        1. Internal Database
        2. Secondary Research
        3. Purchased Database
        4. Primary Research
      3. Data Analysis
        1. Data Validation
        2. Market Size Estimation
        3. Market Forecast Model
      4. Quality Assessment
  1. Introduction: Biosimilars
  2. Executive Summary
    1. Global Market Scenario
    2. Segment Market Scenario
    3. Geographic Market Scenario
    4. COVID-19 Impact
    5. Competitive Landscape
  3. Market Dynamics
    1. Market Drivers
      1. Driver 1
      2. Driver 2
      3. Driver 3
      4. Driver 4
      5. Driver 5
    2. Market Restraint
      1. Restraint 1
      2. Restraint 2
      3. Restraint 3
      4. Restraint 4
    3. Market Opportunities
      1. Opportunity 1
      2. Opportunity 2
      3. Opportunity 3
      4. Opportunity 4
    4. Market Trends
      1. Trend 1
      2. Trend 2
      3. Trend 3
      4. Trend 4
    5. Market Challenges
      1. Challenge 1
      2. Challenge 2
      3. Challenge 3
      4. Challenge 4
  1. Market Environment Analysis
    1. Porter’s 5 Forces Analysis
    2. PESTEL Analysis
    3. Value Chain Analysis
    4. SWOT Analysis
    5. Benchmark
  2. COVID-19 Impact Analysis: Biosimilars Market
    1. COVID-19: Overview
    2. COVID-19 Impact on the Global Market
    3. COVID-19 Impact on the Regional Markets
  3. Market Analysis by Product
    1. Insulin
      1. Insulin Market Forecast, 2021-2029 (USD Million)
    2. Monoclonal antibodies
      1. Monoclonal antibodies Market Forecast, 2021-2029 (USD Million)
    3. Granulocyte Colony- Stimulating Factor
      1. Granulocyte Colony- Stimulating Factor Market Forecast, 2021-2029 (USD Million)
    4. Glucagon
      1. Glucagon Market Forecast, 2021-2029 (USD Million)
    5. Calcitonin
      1. Calcitonin Market Forecast, 2021-2029 (USD Million)
    6. Interferons
      1. Interferons Market Forecast, 2021-2029 (USD Million)
    7. Teriparatide
      1. Teriparatide Market Forecast, 2021-2029 (USD Million)
    8. Erythropoietin
      1. Erythropoietin Market Forecast, 2021-2029 (USD Million)
    9. Follitropin
      1. Follitropin Market Forecast, 2021-2029 (USD Million)
    10. Enoxaparin Sodium
      1. Enoxaparin Sodium Market Forecast, 2021-2029 (USD Million)
    11. Recombinant Human Growth Hormone
      1. Recombinant Human Growth Hormone Market Forecast, 2021-2029 (USD Million)
  1. Market Analysis by Indication
    1. Growth Hormone Deficiency
      1. Growth Hormone Deficiency Market Forecast, 2021-2029 (USD Million)
    2. Oncology
      1. Oncology Market Forecast, 2021-2029 (USD Million)
    3. Inflammatory & Autoimmune Disorders
      1. Inflammatory & Autoimmune Disorders Market Forecast, 2021-2029 (USD Million)
    4. Infectious Diseases
      1. Infectious Diseases Market Forecast, 2021-2029 (USD Million)
    5. Blood Disorders
      1. Blood DisordersMarket Forecast, 2021-2029 (USD Million)
    6. Chronic Diseases
      1. Chronic Diseases Market Forecast, 2021-2029 (USD Million)
    7. Other Indications
      1. Other Indications Market Forecast, 2021-2029 (USD Million)
  1. Regional Market Analysis
    1. Regional Market Trends
    2. Regional Market: Comparative Analysis
  2. North America Biosimilars Market
    1. North America Biosimilars Market
      1. North America Market Size and Forecast, 2021-2029 (USD Million)
        1. Market Size and Forecast by Product, 2021-2029 (USD Million)
        2. Market Size and Forecast by Indication, 2021-2029 (USD Million)
      2. S. Biosimilars Market
        1. S. Market Size and Forecast, 2021-2029 (USD Million)
          1. Market Size and Forecast by Product, 2021-2029 (USD Million)
          2. Market Size and Forecast by Indication, 2021-2029 (USD Million)
        2. Canada Biosimilars Market
          1. Canada Market Size and Forecast, 2021-2029 (USD Million)
            1. Market Size and Forecast by Product, 2021-2029 (USD Million)
            2. Market Size and Forecast by Indication, 2021-2029 (USD Million)
  1. Europe Biosimilars Market
    1. Europe Biosimilars Market
      1. Europe Market Size and Forecast, 2021-2029 (USD Million)
        1. Market Size and Forecast by Product, 2021-2029 (USD Million)
        2. Market Size and Forecast by Indication, 2021-2029 (USD Million)
      2. Germany Biosimilars Market
        1. Germany Market Size and Forecast, 2021-2029 (USD Million)
          1. Market Size and Forecast by Product, 2021-2029 (USD Million)
          2. Market Size and Forecast by Indication, 2021-2029 (USD Million)
        2. UK Biosimilars Market
          1. UK Market Size and Forecast, 2021-2029 (USD Million)
            1. Market Size and Forecast by Product, 2021-2029 (USD Million)
            2. Market Size and Forecast by Indication, 2021-2029 (USD Million)
          2. France Biosimilars Market
            1. France Market Size and Forecast, 2021-2029 (USD Million)
              1. Market Size and Forecast by Product, 2021-2029 (USD Million)
              2. Market Size and Forecast by Indication, 2021-2029 (USD Million)
            2. Spain Biosimilars Market
              1. Spain Market Size and Forecast, 2021-2029 (USD Million)
                1. Market Size and Forecast by Product, 2021-2029 (USD Million)
                2. Market Size and Forecast by Indication, 2021-2029 (USD Million)
              2. Italy Biosimilars Market
                1. Italy Market Size and Forecast, 2021-2029 (USD Million)
                  1. Market Size and Forecast by Product, 2021-2029 (USD Million)
                  2. Market Size and Forecast by Indication, 2021-2029 (USD Million)
                2. Rest of Europe Biosimilars Market
                  1. Rest of Europe Market Size and Forecast, 2021-2029 (USD Million)
                    1. Market Size and Forecast by Product, 2021-2029 (USD Million)
                    2. Market Size and Forecast by Indication, 2021-2029 (USD Million)
  1. Asia Pacific Biosimilars Market
    1. Asia Pacific Biosimilars Market
      1. Asia Pacific Market Size and Forecast, 2021-2029 (USD Million)
        1. Market Size and Forecast by Product, 2021-2029 (USD Million)
        2. Market Size and Forecast by Indication, 2021-2029 (USD Million)
      2. Japan Biosimilars Market
        1. Japan Market Size and Forecast, 2021-2029 (USD Million)
          1. Market Size and Forecast by Product, 2021-2029 (USD Million)
          2. Market Size and Forecast by Indication, 2021-2029 (USD Million)
        2. China Biosimilars Market
          1. China Market Size and Forecast, 2021-2029 (USD Million)
            1. Market Size and Forecast by Product, 2021-2029 (USD Million)
            2. Market Size and Forecast by Indication, 2021-2029 (USD Million)
          2. India Biosimilars Market
            1. India Market Size and Forecast, 2021-2029 (USD Million)
              1. Market Size and Forecast by Product, 2021-2029 (USD Million)
              2. Market Size and Forecast by Indication, 2021-2029 (USD Million)
            2. South Korea Biosimilars Market
              1. South Korea Market Size and Forecast, 2021-2029 (USD Million)
                1. Market Size and Forecast by Product, 2021-2029 (USD Million)
                2. Market Size and Forecast by Indication, 2021-2029 (USD Million)
                3. Market Size and Forecast by Device, 2021-2029 (USD Million)
              2. Australia Biosimilars Market
                1. Australia Market Size and Forecast, 2021-2029 (USD Million)
                  1. Market Size and Forecast by Product, 2021-2029 (USD Million)
                  2. Market Size and Forecast by Indication, 2021-2029 (USD Million)
                2. Rest of Asia Pacific Biosimilars Market
                  1. Rest of Asia Pacific Market Size and Forecast, 2021-2029 (USD Million)
                    1. Market Size and Forecast by Product, 2021-2029 (USD Million)
                    2. Market Size and Forecast by Indication, 2021-2029 (USD Million)
  1. Latin America Biosimilars Market
    1. Latin America Biosimilars Market
      1. Latin America Market Size and Forecast, 2021-2029 (USD Million)
        1. Market Size and Forecast by Product, 2021-2029 (USD Million)
        2. Market Size and Forecast by Indication, 2021-2029 (USD Million)
      2. Brazil Biosimilars Market
        1. Brazil Market Size and Forecast, 2021-2029 (USD Million)
          1. Market Size and Forecast by Product, 2021-2029 (USD Million)
          2. Market Size and Forecast by Indication, 2021-2029 (USD Million)
        2. Mexico Biosimilars Market
          1. Mexico Market Size and Forecast, 2021-2029 (USD Million)
            1. Market Size and Forecast by Product, 2021-2029 (USD Million)
            2. Market Size and Forecast by Indication, 2021-2029 (USD Million)
          2. Argentina Biosimilars Market
            1. Argentina Market Size and Forecast, 2021-2029 (USD Million)
              1. Market Size and Forecast by Product, 2021-2029 (USD Million)
              2. Market Size and Forecast by Indication, 2021-2029 (USD Million)
            2. Rest of Latin America Biosimilars Market
              1. Rest of Latin America Market Size and Forecast, 2021-2029 (USD Million)
                1. Market Size and Forecast by Product, 2021-2029 (USD Million)
                2. Market Size and Forecast by Indication, 2021-2029 (USD Million)
  1. MEA Biosimilars Market
    1. MEA Biosimilars Market
      1. MEA Market Size and Forecast, 2021-2029 (USD Million)
        1. Market Size and Forecast by Product, 2021-2029 (USD Million)
        2. Market Size and Forecast by Indication, 2021-2029 (USD Million)
      2. GCC Biosimilars Market
        1. GCC Market Size and Forecast, 2021-2029 (USD Million)
          1. Market Size and Forecast by Product, 2021-2029 (USD Million)
          2. Market Size and Forecast by Indication, 2021-2029 (USD Million)
        2. South Africa Biosimilars Market
          1. South Africa Market Size and Forecast, 2021-2029 (USD Million)
            1. Market Size and Forecast by Product, 2021-2029 (USD Million)
            2. Market Size and Forecast by Indication, 2021-2029 (USD Million)
          2. Rest of MEA Biosimilars Market
            1. Rest of MEA Market Size and Forecast, 2021-2029 (USD Million)
              1. Market Size and Forecast by Product, 2021-2029 (USD Million)
              2. Market Size and Forecast by Indication, 2021-2029 (USD Million)
  1. Competitor Analysis
    1. Market Share Analysis, 2020 & 2031
    2. Competitive Mapping
    3. Key Players Market Place Analysis
    4. Major Recent Developments
  2. Company Profiles
    1. Novartis AG (Switzerland)
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Product Benchmarking
      5. Recent Developments
    2. Pfizer, Inc. (US)
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Product Benchmarking
      5. Recent Developments
    3. Reddy’s Laboratories Ltd. (India)
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Product Benchmarking
      5. Recent Developments
    4. Amgen, Inc. (US)
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Product Benchmarking
      5. Recent Developments
    5. Eli Lilly and Company (US)
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Product Benchmarking
      5. Recent Developments
    6. Fresenius SE & Co. KGaA (Germany)
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Product Benchmarking
      5. Recent Developments
    7. STADA Arzneimittel AG (Germany)
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Product Benchmarking
      5. Recent Developments
    8. Boehringer Ingelheim (Germany)
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Product Benchmarking
      5. Recent Developments
    9. Gedeon Richter PLC (Hungary)
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Product Benchmarking
      5. Recent Developments
    10. Celltrion (South Korea)
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Product Benchmarking
      5. Recent Developments
    11. Kashiv Biosciences (US)
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Product Benchmarking
      5. Recent Developments
    12. Reliance Life Sciences (India)
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Product Benchmarking
      5. Recent Developments
    13. Thermex (UK)
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Product Benchmarking
      5. Recent Developments
    14. Intas Pharmaceuticals Ltd. (India)
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Product Benchmarking
      5. Recent Developments
    15. Fujifilm Kyowa Kirin Biologics Co., Ltd. (Japan)
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Product Benchmarking
      5. Recent Developments
    16. Others Prominent Players

Conclusion & Recommendations

Select License Type

Buy Now

7 Reasons to Choose EHMR Reports

  • Customer’s Satisfaction

    First and foremost client’s satisfaction, which is very important for Erevna Healthcare and we are committed towards it

  • Client Report

    Customised reports

    Expert in healthcare domain and in depth insights on the report. Erevna Healthcare also customise reports as per the client’s requirement

  • Analyst Support

    Experienced team of analysts with strong background in Pharma, Life Sciences and Biotechnology

  • Assured Quality

    Each report passes through three tiers of quality check

  • Stick to the timeline

    Stick to the timeline

    Erevna Healthcare analysts stick to the timeline

  • Quick delivery

    Quick delivery of reports as per client’s request in three different forms i.e. pdf, ppt and word

  • 24x7 Supprt

    24*7 Support

    24*7 Support post delivery/dispatch of all the reports

Trending Reports